We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces Second Quarter 2012 Operating Results
Key Rolapitant Clinical Trial Results Presented at ASCO and MASCC Meetings In-Licensed Niraparib, a Potentially First and Best-in-Class PARP Inhibitor Raised Over $86.8 Million in Gross Proceeds from an Initial Public Offering WALTHAM, Mass., July 26, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML
Toggle Summary TESARO, Inc. Announces Exercise of Underwriters' Over-Allotment Option
WALTHAM, Mass., July 24, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the underwriters of its initial public offering have partially exercised their over-allotment option for the purchase of an additional 430,183 shares of TESARO common stock.
View HTML
Toggle Summary TESARO, Inc. to Announce Second Quarter 2012 Financial Results on Thursday, July 26th, 2012
WALTHAM, Mass., July 19, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2012 financial results on Thursday, July 26 th , 2012, before the open of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on
View HTML
Toggle Summary TESARO, Inc. Announces Pricing of Initial Public Offering
WALTHAM, Mass., June 27, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock at a price to the public of $13.50 per share. The shares of TESARO's common stock have been approved for listing on the NASDAQ Global
View HTML
Toggle Summary TESARO NAMED AS A 2011 FIERCE 15 BIOTECH COMPANY
Boston, MA – September 6, 2011 – TESARO, Inc., an oncology-focused biopharmaceutical company, announced that it has been named by FierceBiotech today as one of 2011's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry.
View HTML
Toggle Summary TESARO ANNOUNCES $101 MILLION SERIES B FINANCING FOR ADVANCEMENT EXPANSION OF ONCOLOGY PRODUCT PORTFOLIO
- New Capital Funds: Development of Rolapitant through Phase 3 Trials and Potential Regulatory Submissions; Initial Clinical Trial for ALK Inhibitor Program; and Oncology Product Pipeline Expansion – Boston, MA – June 21, 2011 – TESARO, Inc., an oncology-focused biopharmaceutical
View HTML
Toggle Summary EXCLUSIVE LICENSE AGREEMENT WITH AMGEN TO ACQUIRE RIGHTS TO ANAPLASTIC LYMPHOMA KINASE (ALK) PROGRAM
TESARO will be responsible for worldwide development and commercialization Amgen's oral, small molecule ALK inhibitors are highly potent and selective, and possess desirable pharmaceutical properties Recent clinical proof-of-concept has been demonstrated for ALK inhibition in patients with ALK
View HTML
Toggle Summary TESARO AND OPKO HEALTH SIGN EXCLUSIVE LICENSE AGREEMENT FOR
Rolapitant is a Phase III-ready neurokinin-1 (NK-1) receptor antagonist in development for chemotherapy induced nausea and vomiting (CINV) TESARO will be responsible for worldwide development and commercialization Boston, MA and Miami, FL – December 14, 2010 – TESARO, Inc.
View HTML
Toggle Summary TESARO, INC. SECURES $60 MILLION IN START-UP FUNDING
Former MGI PHARMA Executives Found New Oncology-Focused Biopharma Company Initial Financing Provided by New Enterprise Associates (NEA) and Management Boston, MA – May 26, 2010 – TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million
View HTML